RRMM Trial Testing Safety, Efficacy of TAK-169 Therapy Doses First Patient
The first patient has been dosed in a Phase 1 clinical trial testing the safety and efficacy of the CD38-targeting therapy TAK-169…
Myeloma
Pediatric Rare Disease Therapies Increase, But Most Repurposed, Study Finds
The number of treatments for children with rare diseases has grown over the past decade, according to a new study. However, despite the increase, nearly 7,000…
Xpovio Combo Significantly Extends Survival in RRMM, Trial Results Show
Adding Xpovio (selinexor) to Velcade (bortezomib) and low-dose dexamethasone significantly extends survival without signs of disease worsening in people with…
IMF Opens March ‘Resilience’ Campaign for Myeloma Action Month
With an emphasis on the ability of patients and caregivers to adapt to challenges, the International Myeloma Foundation (IMF) is seeking to raise awareness…
Video: Bionews’ Social Media Campaign Highlights #WhatMakesMeRare
In recognition of Rare Disease Day Feb. 29, Bionews Services launched a social media campaign last month asking patients to describe what makes them…
FDA Approves Sarclisa Combo to Treat Advanced Multiple Myeloma
The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc), in combination with Pomalyst (pomalidomide) and dexamethasone,…
Loss of Specific Gene May Help Drive Myeloma Progression, Study Finds
One of the most common genomic defects in multiple myeloma patients is the loss of one copy of chromosome 13, and researchers now suggest that…
CLR 131 Helps Heavily Treated Multiple Myeloma Patients, Phase 2 Data Show
Cellectar Biosciences’ lead candidate CLR 131 safely and effectively prevents disease progression or reduces tumors in people with hard-to-treat multiple myeloma, according…
New CAR T-cell Therapy Shows Early Promise Against Multiple Myeloma in Lab Study
A new CAR T-cell therapy  for people with multiple myeloma has been successfully created and tested in…
Xpovio May Soon Be Available in Israel and Palestinian Authority, Karyopharm Says
Xpovio (selinexor), a treatment for advanced multiple myeloma, may soon be available in Israel and the Palestinian Authority through Promedico, under an exclusive…
